Unlearn Raises $50 Million Series C to Optimize Clinical Research With AI-Powered Digital Twin Technology
Using Novel Digital Twins of Clinical Trial Participants, Unlearn is Accelerating Clinical Research to Help Bring New Treatments to Patients Sooner Unlearn, an AI company creating digital twins of clinical trial participants that enable smaller, faster studies, today announced a $50M Series C round led by Altimeter Capital, joined by returning investors Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital. This round of funding was secured to propel the company’s mission to advance AI to eliminate trial and error in medicine by investing in its people, data, engineering ca...
Source: EMR and HIPAA - February 29, 2024 Category: Information Technology Authors: Healthcare IT News Tags: Health IT Company Healthcare IT 8VC Altimeter Capital Charles Fisher DCVC DCVC Bio Epic Ventures Health IT Funding Health IT Fundings Health IT Investment Insight Partners Mubadala Capital Necessary Venture Capital Pauline Yang Source Type: blogs

Rune Labs Unveils $12 Million Strategic Round to Accelerate Adoption of Novel Parkinson ’s Technologies
Brings Total Raised to Over $42 Million Co-Founder of Nexus NeuroTech and Former Verily President of Medical Devices Jordi Parramon Joins as New Board Member Rune Labs, a precision neurology software and data company, today announced a strategic round of $12 million, increasing the total amount raised by the company to over $42 million. The round was led by new brain disorder fund, Nexus NeuroTech Ventures, with participation from existing investors, including Eclipse, DigiTx Partners, Moment Ventures, and TruVenturo GmbH. Jordi Parramon, PhD, CEO, General Partner, and Co-Founder of Nexus NeuroTech Ventures and former Pre...
Source: EMR and HIPAA - February 6, 2024 Category: Information Technology Authors: Healthcare IT News Tags: Health IT Company Healthcare IT Aspen Neuroscience Benjamin Stecher BlueRock Therapeutics Brian Pepin DigiTx Partners Eclipse Health IT Funding Health IT Fundings Health IT Investment Jordi Parramon Moment Ventures Nexus NeuroTec Source Type: blogs

Drug prices continued: Innovation?
Pharmaceutical manufacturers claim that they need patent protection and marketing exclusivity so they can charge high prices to recoup the costs of drug development and clinical trials. There are a few things wrong with this argument, but they add up to the general fact that the system does not serve the public interest. Drug companies care about one thing only, that is profit. And the pursuit of profit does not serve the interests of public health or social welfare.One obvious mismatch between the goal of public health and the goal of profit is that a relatively cheap drug that you can take once or for a week or so, that ...
Source: Stayin' Alive - January 23, 2024 Category: American Health Source Type: blogs

Best Of CES Health Tech 2024: From Medical Tricorders To AI-Powered Mirrors
The biggest tech event of the year, the Consumer Electronics Show (CES 2024) is happening right now in Vegas! This is the global stage where cutting-edge technologies and innovations debut year after year. From vehicles to smart homes, from robots to food tech all industries are present, but we keep our focus on our topic and introduce the most exciting novelties from the digital health – future of medicine field. 1. The medical tricorder from Withings Withings introduced a device that seems to leap out of a Star Trek episode. Their latest invention, the aptly named BeamO, is a 4 in 1 health monitor. While it i...
Source: The Medical Futurist - January 11, 2024 Category: Information Technology Authors: Andrea Koncz Tags: TMF CES 2024 Source Type: blogs

Biorithm Secures $3.5 Million in Series A Funding to Advance Maternal Care Worldwide
New Funds to Fortify US Market Entry and Growth Strategy, as well as Advance Breakthrough Research Biorithm, a global women’s health medtech, has closed $3.5 million in Series A funding, co-led by Adaptive Capital Partners and SEEDS Capital. With a homegrown spirit and a global vision, Biorithm is dedicated to developing cutting-edge solutions for personalized connected maternity care. The funding will fuel Biorithm’s expansion in Southeast Asia and the United States. It also will assist the company in advancing Femom, a comprehensive obstetric remote monitoring solution, and completing clinical studies to support ...
Source: EMR and HIPAA - December 27, 2023 Category: Information Technology Authors: Healthcare IT News Tags: Health IT Company Healthcare IT Adaptive Capital Partners Amrish Nair Biorithm Health IT Funding Health IT Fundings Health IT Investment Julian Robinson SEEDS Capital Shi Ying Tan Kaixin Source Type: blogs

Science Snippet: Zooming In on Nanoparticles
Nanoparticles come in many different shapes and configurations. Credit: Adapted from Stevens, et. al., under Creative Commons License 4.0. Nanoparticles may sound like gadgets from a science fiction movie, but they exist in real life. They’re particles of any material that are less than 100 nanometers (one-billionth of a meter) in all dimensions. Nanoparticles appear in nature, and humans have, mostly unknowingly, used them since ancient times. For example, hair dyeing in ancient Egypt involved lead sulfite nanoparticles, and artisans in the Middle Ages added gold and silver nanoparticles to stained-glass windows. Over...
Source: Biomedical Beat Blog - National Institute of General Medical Sciences - December 13, 2023 Category: Research Authors: Chrissa Chverchko Tags: Chemistry, Biochemistry and Pharmacology Tools and Techniques Cool Tools/Techniques Cool Videos Medicines Science Snippet Source Type: blogs

A Longevity Industry Feature in Biopharma Dealmakers: Repair Biotechnologies, Deciduous Therapeutics, and More
In this study, a single treatment at the peak of disease resulted in the ablation of senescent cells in the lung and attenuation of key fibrotic and inflammatory markers, which ultimately resolved fibrosis. Deciduous Therapeutics has used computational assisted design to synthesise a suite of proprietary therapies that could be used in the clinic to re-activate tissue-resident iNKT cells. To date, the company's lead program has shown single-dose efficacy in resolving both metabolic and fibrotic diseases along with a favorable safety profile at doses significantly higher than the efficacious dose. (Source: Fight Aging!)
Source: Fight Aging! - December 4, 2023 Category: Research Authors: Reason Tags: Longevity Industry Source Type: blogs

Your Insulin of the Future Could Be " Made in China " if Big PBMs Have a Say in the Matter
Back on June 16, 2022, I published an article on LinkedIn entitled "How the Civica Insulin Announcement May Be Disruptive to the PBM Kickback Scheme" (see the article athttps://www.linkedin.com/pulse/how-civica-insulin-announcement-may-disruptive-pbm-scheme-strumello/ if you wish to read it) which predicted that a growing number of insulin biosimilars whose active pharmaceutical ingredients (API ' s) are cultured in offshore laboratories are forecast to hit the U.S. market in the next few years. According to the FDA and the individual companies whom I also follow on LinkedIn, the U.S. Food and Drug Administration (FDA) typ...
Source: Scott's Web Log - October 15, 2023 Category: Endocrinology Tags: 2023 Congress insulin insulin prices lawmakers PBM Pharmacy Benefit Managers Source Type: blogs

Fight Aging! Newsletter, October 9th 2023
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - October 8, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

A Outsider's Popular Science View of the Longevity Industry and Academia
A brace of popular science articles on aging research were recently published at the Economist. Like many of these views from a distance written by journalists on the outside, peering into the field, one must assume that its existence is largely the result of the sizable investments made over the last two years into the development of therapies based on partial reprogramming. The Altos Labs funding in particular represented a meaningful fraction of all investment into biotech made that year. That tends to attract attention. From there, an investigator would notice an additional broad focus on cellular senescence, many comp...
Source: Fight Aging! - October 2, 2023 Category: Research Authors: Reason Tags: Healthy Life Extension Community Source Type: blogs

How Policy Changes Can Fix Market Distortions in Healthcare and Improve the Country ’s Debt
The following is a guest article by Zach Markin, Co-Founder and CEO at HTD Health American healthcare is the most dysfunctional industry in our country. Historically, it is the most prolific driver of family bankruptcy, and now it is on its way to bankrupting our country collectively. A major justification for President Biden’s tax hike proposal is to shore up the tenuous finances of Medicare whose trust fund is forecasted to be depleted by 2028. While this is important, such efforts address the symptoms of a dysfunctional industry rather than the root causes. While the near-term liquidity and long-term financial health ...
Source: EMR and HIPAA - September 12, 2023 Category: Information Technology Authors: Guest Author Tags: Ambulatory C-Suite Leadership Health IT Company Healthcare IT Hospital - Health System Regulations Revenue Cycle Management AMA Healthcare Barriers Healthcare Costs healthcare industry Healthcare Perverse Incentives HTD Health Me Source Type: blogs

Trials of Xenotransplantation of Pig Organs into Humans Continue
Researchers have genetically engineered pigs to overcome the known barriers to transplantation of pig organs into humans, and have reached the stage of conducting transplants into terminally ill volunteers and brain dead individuals who donated their bodies to science. To learn by doing is really the only practical way by which the presently unknown problems are discovered. This trial of kidney transplantation ran for longer than prior efforts, and is a step on the path to producing a ready supply of non-human organs for transplantation, a technology that will compete with efforts to grow new organs on demands. Su...
Source: Fight Aging! - August 24, 2023 Category: Research Authors: Reason Tags: Daily News Source Type: blogs

Proprio Raises $43M Series B Funding to Fuel Commercialization
First Light Field-Enabled Surgical Technology Company Secures Additional Institutional Capital to Drive Adoption of its AI-Driven Platform Proprio, a Seattle-based surgical technology company, today announced that it has secured $43 million in Series B funding from new and existing investors. The capital fuels commercialization to address significant demand for Proprio’s AI-driven surgical navigation platform in the US and overseas. Proprio’s flagship surgical navigation platform, Paradigm™, achieved a significant milestone this year by obtaining 510(k) clearance from the U.S. Food and Drug Administration (FDA). ...
Source: EMR and HIPAA - August 17, 2023 Category: Information Technology Authors: Healthcare IT News Tags: Health IT Company Healthcare IT Alf Grunwald Bird B. AG FDA Gabriel Jones Health IT Funding Health IT Fundings Health IT Investment PARADIGM Proprio Source Type: blogs

What Is Pharmacology?
Credit: iStock. Pharmacology is the study of how molecules, such as medicines, interact with the body. Scientists who study pharmacology are called pharmacologists, and they explore the chemical properties, biological effects, and therapeutic uses of medicines and other molecules. Their work can be broken down into two main areas: Pharmacokinetics is the study of how the body acts on a medicine, including its processes of absorption, distribution, metabolism, and excretion (ADME). Pharmacodynamics is the study of how a medicine acts in the body—both on its intended target and throughout all the organs and tissue...
Source: Biomedical Beat Blog - National Institute of General Medical Sciences - August 14, 2023 Category: Research Authors: Chrissa Chverchko Tags: Being a Scientist Chemistry, Biochemistry and Pharmacology Common questions Genomics Medicines Miniseries Source Type: blogs

Neurotech, neuroethics and brain data in context: Are “neurorights” the way to mental privacy?
This article was originally published on The Conversation. To Learn More: Brain Data in Context: Are New Rights the Way to Mental and Brain Privacy? (AJOB Neuroscience). From the Abstract: The potential to collect brain data more directly, with higher resolution, and in greater amounts has heightened worries about mental and brain privacy … To better understand the privacy stakes of brain data, we suggest the use of a conceptual framework from information ethics, Helen Nissenbaum’s “contextual integrity” theory. To illustrate the importance of context, we examine neurotechnologies and the information flows th...
Source: SharpBrains - August 10, 2023 Category: Neuroscience Authors: The Conversation Tags: Brain/ Mental Health Technology & Innovation brain data brain privacy Brain-Computer Interfaces contextual integrity mental privacy neural data neurotechnologies Neurotechnology Source Type: blogs